Alembic Suffers 38% Slide In US As Price Erosion Bites
But Company Insists Long-Term View Of Market Remains ‘Intact’
India’s Alembic has reported a 38% drop in its US generics business in the first quarter of its FY22 financial, due to price erosion stemming from increased competition. The company plans to launch four generics in the US in the coming quarter.
